Clinical trial
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
NCT04659044 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
- Lead sponsor
- Academic and Community Cancer Research United
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 1, 2021
- Completion date
- March 29, 2024
- Enrollment
- 3 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent b-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, refractory b-cell non-hodgkin lymphoma, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3a follicular lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory small lymphocytic lymphoma